sorafenib has been researched along with withanolides in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (withanolides) | Trials (withanolides) | Recent Studies (post-2010) (withanolides) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 789 | 1 | 647 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, MS; Cohen, SM; Mukerji, R; Samadi, AK; Timmermann, BN | 1 |
| Chakraborti, A; Kanthaje, S; Kaur, H; Kaur, R; Makol, A; Sharma, S | 1 |
2 other study(ies) available for sorafenib and withanolides
| Article | Year |
|---|---|
A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma; Carcinoma, Papillary; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Withanolides | 2012 |
Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Hepatocellular; Cell Survival; Chromatography, High Pressure Liquid; Down-Regulation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Proteomics; Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Vimentin; Withanolides | 2020 |